Question to the Department of Health and Social Care:

To ask Her Majesty's Government what plans, if any, they have to introduce preventative antibody therapies to mitigate the risks of COVID-19 for clinically extremely vulnerable individuals.

The RAPID C-19 collaboration has enabled multi-agency oversight of national and international trial evidence as it emerges for COVID-19 therapies in potential treatment and prophylactic indications. The RAPID C-19 collaboration actively reviews all promising compounds to assess whether these should be considered for potential use in the National Health Service. The evidence has most strongly supported treatment rather than prophylaxis. The evidence on preventative use will continue to be reviewed for efficacy and safety.